Kornimate/medical-research-clean huggingface dataset:
evaluation of musculoskeletal system symptoms and biochemical parameters in covid-19

Conditions: Covid19

Summary: the neutrophil-lymphocyte ratio (nlr) used to demonstrate inflammatory status in recent years can be calculated by dividing the absolute neutrophil count by the absolute lymphocyte count at routine blood tests.

dysregulation in immune responses has been reported in association with hyperinflammation in covid-19 patients, nlr has been linked to the severity of the patient's clinical status, and an increase in nlr is reported to be an independent risk factor for in-hospital mortality. pain is a frequently seen symptom at the onset of viral infections and throughout the course of the disease. although the pain mechanisms triggered by viral pathogens are not yet entirely understood, pain is thought to arise as a result of direct activation of nociceptor neurons by pathogens and their interaction with molecular ligands. toll-like receptor 7 (tlr7), a pathogen recognition receptor that plays an important role in immune responses to viruses by binding to viral rna, is known to be involved in pain development in different rna virus infections. park et al. showed that extracellular micro rnas activate nociceptive neurons via the tlr7 pathway. although these mechanisms have been demonstrated for different viral infections, the viral pathogenesis leading to pain in covid-19 is still unclear. the purpose of this study was to investigate the prevalence of headache and muscular pain in patients diagnosed with covid-19 and to determine the relationship between these symptoms and inflammatory parameters.

Eligibility criteria:
inclusion criteria: * aged 18-70 * diagnosed with covid-19 exclusion criteria: * patients with suspected sars-cov-2 infection, with two negative rt-pcr tests, hospitalized in the intensive care unit during inclusion in the study * musculoskeletal pains in the previous three months, with diseases capable of causing myalgia prior to diagnosis (such as fibromyalgia and inflammatory muscle disease) * cognitive disorders capable of preventing history-taking and physical examination such as mental disability and dementia, * previous history of headache (migraine, tension type headache)

Keywords: pain
evaluation of the effect of a clinical exercise programme on plantar distribution and correction of postural asymmetries

Conditions: This Study Highlights Differences in Baropodometry Between Genders

Summary: the aim of this study was to identify significant variables that contribute to the association between postural problems, plantar pressure distribution and levels of bodily pain in middle-aged and elderly adults. the researchers' hypothesis is that plantar pressure characteristics and postural asymmetries differ according to gender, are related to body composition and predict pain levels. the study described here is the only one to include variables that make it possible to identify body asymmetries in a postural analysis, based on the distribution of plantar pressure and body composition.

the study employed an observational cross-sectional design. a convenience sample was recruited to analyse differences between men and women in anthropometrics, body composition, plantar pressure distribution, and pain levels. without intervention, researchers observed and recorded data at a single time point, allowing comparisons between sexes and exploring correlations among the measured variables. this type of design allowed a snapshot view of the differences and associations present within the sample.

Eligibility criteria:
inclusion criteria: * participants had to be at least eighteen years old and physically fit. all participants had to complete the par-q (health questionnaire), psychological well-being questionnaire (ebep) and sign the free, informed and informed consent form (clie). exclusion criteria: * in order to reduce the risk of injury or aggravation of known diseases, the researchers chose the following exclusion criteria: serious orthopaedic problems (prosthesis fitting, recent orthopaedic surgery), reported neurological problems (requiring daily medication), cardiopulmonary diseases (pacemaker, use of oxygen cylinders) and pregnant women.

Keywords: baropodometry, bioimpedance, artificial intelligence
metabolic health benefits of dairy protein

Conditions: Hyperlipidemia; Obesity

Summary: the purpose of this study is to evaluate the effects of regular low fat diary consumption on markers of cardiovascular (cv) and metabolic (cardiometabolic) health including body composition (% body fat, body weight), blood lipids, blood glucose, arterial compliance, blood pressure, insulin sensitivity and resting metabolic rate.

this is a multi-centre, randomized, dietary intervention study of 12 months. a total of 100 overweight/obese individuals will be recruited, half recruited in adelaide, south australia and the other half from manitoba, canada. at baseline, subjects assigned to hd will be given standard serves of low fat dairy products (eg. 250ml milk, 200g yoghurt) on a regular basis for 6 months and asked to incorporate 4 serves/day into their diet. volunteers randomized to the ld will be asked to continue with their habitual diet and consume less than 2 serves of dairy on a regular basis for 6 months. all participants will be asked to complete a food frequency questionnaire, physical activity diary, 3-day food record, and keep a record of dairy serves (food log) consumed each day. in total, participants will be asked to come to the centre 5 times throughout the study. however, the hd group will be asked to return to the centre every two weeks to receive diary product and return dairy record (food log). at baseline subjects will be asked to attend the richardson centre for functional foods and nutraceuticals (rcffn) fasted for various measurements including: body weight, blood pressure, arterial compliance, dual energy x-ray absorptiometry (dexa) scan for measurement of body fat, abdominal fat and bone mineral density, waist and hip circumferences and provide a blood sample for the measurement of blood lipids, insulin and glucose.

Eligibility criteria:
inclusion criteria: * bmi ≥25 kg/m2, assessed as age-related healthy based on pre-study screening examination including: * medical history * diet and lifestyle history * physical measurements (height, weight and blood pressure). exclusion criteria: * pregnancy or likely to be pregnant (ionizing radiation from dexa) * weight ≥135kg (exceeds the capacity of the dexa scanner)diagnosed diabetes or cardiovascular disease * liver or renal disease * regular use of appetite suppressants * irregular use of other treatments which might interfere with the outcomes of the study (e.g anti-hypertensives, statins, thyroxine, omega-3 supplements etc).

Keywords: body weight lipids glucose insulin
julina post-marketing surveillance for postmenopausal osteoporosis in japan

Conditions: Osteoporosis, Postmenopausal

Summary: this study is a regulatory post-marketing surveillance in japan, and it is a local prospective and observational study of patients who have received julina for postmenopausal osteoporosis. the objective of this study is to assess safety and efficacy of using julina in clinical practice. a total 100 patients will be recruited and followed 3 years since starting julina administration.


Eligibility criteria:
inclusion criteria: * patients who received julina for postmenopausal osteoporosis exclusion criteria: * patients who are contraindicated based on the product label

Keywords: julina postmenopausal osteoporosis
a prospective study of constructing immune repertoire to monitor the therapeutic effect in nsclc patients

Conditions: Non-small Cell Lung Cancer

Summary: this study is designed to evaluate the untreated nsclc patients. after participants have accepted chemotherapy, radiotherapy, and immunotherapy, the investigators used the next generation sequence technology (ngs) to construct immune repertoire to detective variation of patients' immune state and to monitor patients' therapeutic effect. the investigators are aim to explore the novel clone sequence as potential therapy target.

lung cancer was one of the most deadly tumors in the world. the standard of care for patients is platinum-based doublet chemotherapy concurrent with radiotherapy. as for patients with a mutant epidermal growth factor receptor (egfr) and anaplastic lymphoma kinase(alk), egfr or alk tyrosine kinase inhibitors (tkis) are the standard first-line therapy. now, the food and drug administration approved ipilimumab, nivolumab, and pembrolizumab as first-line or second-line therapy for nsclc. however, there was no reports about therapeutic effect for nsclc patients through detecting herself immune state, immune repertoire could explore patients' immune clonality and diversity using ngs technology.the investigators look forward to illuminate the mechanism of patients antitumor action.

Eligibility criteria:
inclusion criteria: * pathologically verified stage iv non-small cell lung cancer without treated. * eastern cooperative oncology group (ecog) performance status of 0 or 1 * major organs function normally * women at pregnant ages should be under contraception * willing and able to provide informed consent exclusion criteria: * pathology is mixed type• * poor vasculature * coagulopathy, or ongoing thrombolytics and/or anticoagulation * blood-borne infectious disease, e.g. hepatitis b * history of mandatory custody because of psychosis or other psychological disease inappropriate for treatment deemed by treating physician * other conditions requiring exclusion deemed by physician

Keywords: t cell repertoire lung cancer tumor mutation burden circulating tumour dna
clinical and histopathologic characteristics of bap1 mutations

Conditions: Malignant Pleural Mesothelioma (MPM); Choroidal Nevus; Primary Uveal Melanoma (UM); Metastatic Uveal Melanoma (UM); Renal Cell Carcinoma; Cholangiocarcinoma

Summary: the goal of this protocol is to determine the prevalence of somatic and germline mutations in bap1 (brca associated protein-1) among patients with mesothelioma , choroidal nevus, primary uveal melanoma (um), or metastatic um seen at our institution.


Eligibility criteria:
inclusion criteria: all consents: * \> or = to 18 years of age * ability to provide informed consent consent 1: mesothelioma * histologically proven diagnosis of mesothelioma or choroidal nevus * diagnosis of choroidal nevus by direct examination and/or ultrasound/optical coherence tomography and possibly fluorescein angiography or primary uveal melanoma * diagnosis of uveal melanoma by direct examination and/or ultrasound/optical coherence tomography and possibly fluorescein angiography consent 2: mesothelioma * histologically proven diagnosis of mesothelioma and * bap1 mutation or loss of expression identified in tumor sample or one of the following: * age\<50 at diagnosis * no history of asbestos exposure * personal history of choroidal nevus, uveal melanoma, melanoma, renal cell carcinoma, or cholangiocarcinoma * family history of choroidal nevus, uveal melanoma, mesothelioma, renal cell carcinoma, or cholangiocarcinoma * history of malignancy in more than two first-degree relatives or choroidal nevus * diagnosis of choroidal nevus by direct examination and/or ultrasound/optical coherence tomography and possibly fluorescein angiography and one of the following: * more than one clinical risk factor, which may include: orange pigment, thickness \> 1 \< 2.5mm * personal history of uveal melanoma, skin melanoma, mesothelioma renal cell carcinoma, or cholangiocarcinoma * family history of choroidal nevus, uveal melanoma, mesothelioma renal cell carcinoma, or cholangiocarcinoma or primary uveal melanoma * diagnosis of uveal melanoma by direct examination and/or ultrasound/optical coherence tomography and possibly fluorescein angiography and one of the following: * personal history of uveal melanoma, skin melanoma, mesothelioma, renal cell carcinoma, or cholangiocarcinoma * family history of choroidal nevus, uveal melanoma, mesothelioma, renal cell carcinoma, or cholangiocarcinoma * history of malignancy in more than two first-degree relatives or metastatic uveal melanoma * histologically proven diagnosis of metastatic uveal melanoma and * bap1 mutation or loss of expression identified in tumor sample or one of the following: * personal history of uveal melanoma, skin melanoma, mesothelioma renal cell carcinoma, or cholangiocarcinoma * family history of choroidal nevus, uveal melanoma, mesothelioma renal cell carcinoma, or cholangiocarcinoma * history of malignancy in more than two first-degree relatives consent 3: * relative of patient with germline bap1 mutation identified through identified testing exclusion criteria: * none

Keywords: somatic germline mutations bap1 (brca associated protein-1) 12-235
comparison between two techniques of subthreshold diode laser cyclophotocoagulation in refractory glaucoma

Conditions: Refractory Glaucoma

Summary: the aim of this study is to assess the results of subliminal subthreshold transscleral diode cyclophotocoagulation in refractory glaucoma using the standard technique of 360 degree application and to compare the outcome with a modified technique both in terms of efficacy and safety.

refractory glaucoma is glaucoma that doesn't respond favorably to surgical and/or medical treatment to lower intraocular pressure. it can include primary open angle glaucoma, primary angle closure glaucoma, neovascular glaucoma or silicone oil-induced glaucoma. cyclophotocoagulation (cpc) is a form of cycloablation using laser to treat glaucoma. it involves ciliary body destruction by targeting the ciliary epithelium and stroma, resulting in a reduction in aqueous secretion and hence intraocular pressure. transscleral cyclophotocoagulation using a continuous diode laser has been a treatment option in advanced glaucoma cases with s¬¬uboptimal iop control, for a long time. high treatment energy used by diode laser cyclophotocoagulation was argued to be associated with increased frequency of serious complications such as vision loss, hypotony, and phthisis. these concerns necessitate modulation of the parameters of laser treatment used. micropulse transscleral cyclophotocoagulation (mp-tscpc), which is a variation of conventional continuous-wave cpc, has emerged as an attractive alternative for the treatment of many types of glaucoma. it breaks the continuous wave laser into multiple short and repetitive pulses that allow the tissue to cool down between applications, thus reducing thermal damage. this strategy delivers very short energy pulses followed by rest periods, which is known as "duty cycle" and is defined as the ratio of time that a laser is delivering energy vs resting (on/off). for this procedure, an infrared diode laser is used to stimulate the ciliary body structures and the uveoscleral pathway. this way it reduces the production of the aqueous humour and facilitates the uveoscleral outflow, with iop reduction as a final effect. despite promising results, only few clinical studies are published on mp-tscpc and most of them are retrospective studies refer to patients having previous continuous wave transscleral cyclophotocoagulation. moreover, several parameters and protocols have been studied in other reports in an attempt to refine the standard technique aiming to improve the outcomes without increasing the adverse effects.

Eligibility criteria:
inclusion criteria: * patients with refractory glaucoma (iop \> 21 mmhg unresponsive to maximally tolerated antiglaucoma medications, previously failed surgical treatment, or both) exclusion criteria: * ocular inflammation. * ocular infection. * recent ocular surgery in the study eye in the 2 months prior to enrolment.
zanzalintinib versus everolimus in participants with locally advanced or metastatic neuroendocrine tumors

Conditions: Pancreatic Neuroendocrine Tumor (pNET); Extra-Pancreatic Neuroendocrine Tumor (epNET)

Summary: the primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.


Eligibility criteria:
key inclusion criteria: * histologically confirmed, locally advanced/unresectable or metastatic, well-differentiated grade 1, 2, or 3 nets of pancreatic origin or extra-pancreatic origin. * allowed prior lines of therapy, based on the site of net and functional status. * documented radiographic disease progression per recist 1.1, as assessed by the investigator based on imaging assessments (computed tomography \[ct\] or magnetic resonance imaging \[mri\]) within 12 months before randomization. * measurable disease according to recist 1.1 as determined by the investigator. * archival tumor tissue is required, if available. if archival tumor tissue is not available, a fresh biopsy may be submitted if it can be safely and feasibly obtained. every attempt should be made to provide tumor tissue. key exclusion criteria: * histologically confirmed neuroendocrine carcinomas (including small cell lung cancer), medullary thyroid cancer, pheochromocytoma, paraganglioma, merkel cell carcinoma, and mixed neuroendocrine non-neuroendocrine neoplasm (minen). * prior treatment with a vascular endothelial growth factor receptor (vegfr) -targeting tyrosine kinase inhibitor or a mammalian target of rapamycin (mtor) inhibitor. * systemic chemotherapy and any liver-directed or other ablative therapy within 4 weeks before randomization. * systemic radionuclide therapy within 6 weeks before randomization. * radiation therapy for bone metastases within 2 weeks, any other radiation therapy, except as indicated above, within 4 weeks before randomization. note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: metastatic cancer locally advanced cancer neuroendocrine tumor (net)
robot-assisted pyeloplasty in young children

Conditions: Ureterohydronephrosis; Ureter Obstruction; Child, Only

Summary: the goal of this retrospective study is to analyse the outcomes of robot-assisted pyeloplasty in participants younger than 5 years old: * indication criteria * clinical symptoms * operating time * length of stay * complications * follow-up

outcomes of robot-assisted pyeloplasty in participants younger than 5 years old and comparison with the outcomes in the literature.

Eligibility criteria:
inclusion criteria: * patients younger than 5 years old, who underwent primary robotic pyeloplasty, was launched between january 2014 and december 2022 exclusion criteria: * patients older than 5 years old, who underwent primary robotic pyeloplasty, was launched between january 2014 and december 2022

Keywords: robot-assisted pyeloplasty child retrospective study
mri perfusion on t1 and t2 brain lesion(s)

Conditions: Lung Carcinoma Metastatic to the Brain

Summary: this study therefore aims to assess current treatment recommended by scientific societies \[ 6-13 \] , brain mri with injection of contrast for the diagnosis and monitoring of brain metastases . the recommended dose of this examination gadolinium is from 0.1 to 0.3 mmol / kg \[ 14 \] . sequences infusion different from one center to the other made : some use the infusion t1, other infusion t2 \* . no recommendation establishes whether it is preferable to use one or the other of these sequences. no examination is added for the purposes of protocol. indications for mri and the number and timing of mri checks under this protocol are consistent with what is done in practice . the used type of gadolinium and the injected dose will be identical for both sequences infusion . the assessment shall not in any case the contrast but the interpretation of the sequence itself. special procedures monitoring implemented embodiment correspond to the two sequences instead of infusion (one of t1-weighted and t2 \* in the other ) , in the original mri and mri of the first control , in order to compare their effectiveness

eligibility criteria: * major patients * addressed mri for initial assessment of brain metastases * at a suspicion of one or more brain metastases in the brain scanner routine screening * follow for lung cancer histologically documented * in the thoracic oncology service professor lafitte (contact: dr cortot) * to whom treatment with chemotherapy or targeted therapy (including anti-angiogenic) is considered * be socially insured main outcomes measures: comparing the area under the roc curve of different parameters evaluated in t1 and t2 \* perfusion during the initial assessment for the diagnosis of maximal tumor response evaluated at 1 year

Eligibility criteria:
inclusion criteria: * major patients * addressed to mri for initial assessment of brain metastases * at a suspicion of one or more brain metastases in the brain scanner routine screening * followed for lung cancer histologically documented in the thoracic oncology service of professor lafitte (contact: dr cortot) * to whom treatment with chemotherapy or targeted therapy (including anti-angiogenic) is considered * be socially insured- exclusion criteria: * absolute contraindication to mri (pacemaker, implantable pacemaker, metallic foreign body intraorbital) * patients minors under guardianship / curatorship * patients with impaired judgment skills or unable to receive information * pregnant women * patients for which lesions are not compatible with lung metastases * patients with brain metastases or already known and explored mri * patients for whom treatment by surgical excision of brain metastases is considered

Keywords: mri perfusion therapeutic response chemotherapy brain metastases
paraffin oil or coconut oil in acute aluminum phosphide poisoning

Conditions: Aluminum Phosphide Poisoning

Summary: the aim of the present study is to evaluate safety and efficacy of gastric lavage with paraffin oil or gastric lavage with coconut oil in management of acute aluminum phosphide poisoning.

60 patients will be randomly assigned as control groups, paraffin group, and coconut group in a 1:1:1 ratio (30 patients in each group). inclusion criteria: * patients with symptomatic acute aluminum phosphide poisoning * age is more than 12 years of both gender * patients presenting within 6 hours post-ingestion of aluminum phosphide (papade and vanjari, 2019). the diagnosis is made on the basis of: 1. the suggestive clinical manifestations due to and following shortly after a single exposure to aluminum phosphide. 2. reliable identification of the compound based on the container brought by patient attendants. 3. biochemical detection of phosphine gas in gastric aspirate (silver nitrate test). * group (i): gastric lavage with saline and sodium bicarbonate 8.4% then aspiration will be done after 3-5 min through nasogastric tube (control group) * group (ii): gastric lavage will be initiated with 50 ml of paraffin oil and 50 ml of sodium bicarbonate solution 8.4%, then aspiration will be done after 3-5 min through nasogastric tube (paraffin group). * group (iii): gastric lavage will be initiated with 50 ml coconut oil and 50 ml sodium bicarbonate 8.4 % then aspiration will be done after 3-5 min through nasogastric tube (coconut group). * all patients will continue to receive the standard supportive treatment according to tanta university poison control center protocol, which is determined by the attending physician who maintains clinical responsibility for all patients. conventional standard treatment included using inotropes, fluids and electrolytes resuscitation, intubation, mechanical ventilation and antiarrhythmic agents if indicated.

Eligibility criteria:
inclusion criteria: * • patients with symptomatic acute aluminum phosphide poisoning * age is more than 12 years of both gender * patients presenting within 6 hours post-ingestion of aluminum phosphide exclusion criteria: * • patients less than 12 years of age * pregnant and lactating women. * patients with ingestion or exposure to other substances in addition to aluminum phosphide. * patients with other major medical conditions (e.g. cardiovascular disease, diabetes mellitus, renal or hepatic failure).